Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-03-22
2011-03-22
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S183000
Reexamination Certificate
active
07910624
ABSTRACT:
The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.
REFERENCES:
patent: 3471513 (1969-10-01), Leland et al.
patent: 4008323 (1977-02-01), Cousse et al.
patent: 4011336 (1977-03-01), Amann et al.
patent: 4026896 (1977-05-01), Harita et al.
patent: 4031243 (1977-06-01), Aparicio et al.
patent: 4058558 (1977-11-01), Cousse et al.
patent: 4131617 (1978-12-01), Esanu
patent: 4176193 (1979-11-01), Esanu
patent: 4234599 (1980-11-01), Van Scott et al.
patent: 4671901 (1987-06-01), Green
patent: 4699926 (1987-10-01), Abraham et al.
patent: 4704402 (1987-11-01), Abraham et al.
patent: 4723958 (1988-02-01), Pope et al.
patent: 4731381 (1988-03-01), Abraham et al.
patent: 4732914 (1988-03-01), Morton, Jr.
patent: 4735967 (1988-04-01), Neesby
patent: 4747825 (1988-05-01), Linkie et al.
patent: 4751244 (1988-06-01), Abraham et al.
patent: 4820711 (1989-04-01), Pearlman
patent: 4822821 (1989-04-01), Perrine
patent: 4849426 (1989-07-01), Pearlman
patent: 4851229 (1989-07-01), Magruder et al.
patent: 4853388 (1989-08-01), Pearlman
patent: 4925873 (1990-05-01), Friedhoff et al.
patent: 4948592 (1990-08-01), Ayer et al.
patent: 4952560 (1990-08-01), Kigasawa et al.
patent: 4965251 (1990-10-01), Stamatoyannopoulos
patent: 4997815 (1991-03-01), Perrine et al.
patent: 5023251 (1991-06-01), Sattler et al.
patent: 5025029 (1991-06-01), Perrine
patent: 5032507 (1991-07-01), Yu et al.
patent: 5039703 (1991-08-01), Breuer
patent: 5081124 (1992-01-01), Hughes
patent: 5137734 (1992-08-01), Spiegeman et al.
patent: 5185436 (1993-02-01), Villa et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5208333 (1993-05-01), Paul et al.
patent: 5258367 (1993-11-01), Bazer et al.
patent: 5270458 (1993-12-01), Lemischka
patent: 5378716 (1995-01-01), Hamanaka et al.
patent: 5403590 (1995-04-01), Forse
patent: 5635532 (1997-06-01), Samid
patent: 5939456 (1999-08-01), Perrine
patent: 6011000 (2000-01-01), Perrine et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6451334 (2002-09-01), Perrine
patent: 1209037 (1986-08-01), None
patent: 0224599 (1985-11-01), None
patent: 0320726 (1988-12-01), None
patent: 0371789 (1989-11-01), None
patent: 0617966 (1989-11-01), None
patent: 371789 (1990-06-01), None
patent: 2126082 (1983-08-01), None
patent: WO 92/04913 (1992-04-01), None
patent: WO 93/07866 (1993-04-01), None
patent: WO 93/18761 (1993-09-01), None
patent: WO9511699 (1995-05-01), None
patent: WO9627369 (1996-09-01), None
patent: WO9804290 (1998-02-01), None
Volkov, I. I. et al., 1967, CA:66:91411m, abstract, 1967.
Wittstruck, et al., 1967, CA:67:59315, abstract, 1967.
Canceill et al., 1970, CA:73:65917, abstract, 1970.
Faucitano et al., 1967, CA:68:110268, abstract, 1967.
El-Nawawy et al., 1970, CA:74:141218, abstract, 1970.
J. Biochem. (Tokyo) vol. 115, No. 3, 1994, pp. 540-544, XP000574711 Endo T., et al.: “Differential Induction of Adult and Fetal Globin Gene Expression in the Human CML Cell Subline KU-812F/33”.
Fund Appl. Toxicol., vol. 2, No. 4, 1982, pp. 158-160, XP000574523 Miller RR. et al.: “Toxicity of methoxyacetic acid in rats”.
Chem.-Biol, Interactions, vol. 70, 1989, pp. 339-352, XP000574611 Ghanayem B. I. et al.: “Structure-activity relationships for the in vitro hematotoxicity of N-alkoxyacetic acids, the toxic metabolites of glycol ethers”.
“Abstract”, D.M. McCafferty et al.,Int. J. Tissue React. 1989; 11(4): 165-8.
“Abstract”, J.M. Harig et al,N. Engl. J. Med. Jan. 5, 1989; 320(1): 23-8.
“Abstract”, D.M. McCafferty et al,Agents Actions1992; Spec. No. C79-81.
“Abstract”, W. Scheppach et al,GastroenterologyJul. 1992; 103(1): 336-8.
“Abstract”, W.E. Roediger et al,LipidsOct. 1990; 25(10): 646-52.
“Abstract”, R.I. Breuer et al,Dig. Dis. Sci. Feb. 1991; 36(2): 185-7.
“Abstract”, P. Planchon et al, In Vivo Nov.-Dec. 1992; 6(6) 605-10.
“Abstract”, P. Planchon et al,Anticancer Res. Nov.-Dec. 1992; 12(6B): 2315-20.
“Abstract”, S.J. Guadet et al,Neruochem Int. Mar. 1993; 22(3): 271-5.
“Abstract”, C.D. Gerharz et al.,Clin. Exp. MetastasisJan. 1993; 11(1): 55-67.
“Abstract” , D. Garsetti et al,Biochem J. Dec. 15, 1992; 288(pt 3): 831-7.
“Abstract”, T. Boulikas,Anticancer Res. May-Jun. 1992; 12(3): 885-98.
“Abstract”, M.M. Belcheva et al,J. Pharmacol. Exp. Ther. Oct. 1991; 259(1): 302-9.
“Abstract”, F.M. Foss, et al.,The American Society of Hematology, 35th Annual Meeting, Dec. 3-7, 1993.
“Activiation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate”, Gordon D. Ginder et al.,Proc. Natl. Acad. Science, USA , vol. 81. pp. 3954-3958, Jul. 1984.
An Interleukin 2/Sodium Butyrate Combination as Immunotherapy for Rat Colon CancerPeritoneal carcinomatosis, Gastroenterology, vol. 107, pp. 1697-1708. 1994.
“An Outlier Theory of Cancer Curability—Tumor Cell Differentiation as a Therapeutic Goal”, Eric J. Seifter et al,The American Journal of Medicine, vol. 83. Oct. 1987, pp. 757-60.
“Anti-Lekemic Effect of Butyrate In-Vitro and In-Vivo and the Development of a Potent Butyrate Prodrug”, A. Rephaeli, et al.,Blood, vol. 76, p. 115a, 1990.
“Antitumor Effect of Arginine Butyrate in Conjunction withCorynebacterium parvionand Interferon”, Charles Chany et al,Int. J. Cancer: 30, (1982) pp. 489-493.
“Augmentation of Cysteamine-Induced Ulceration of Rat Duodenum by Systemically Administered γ-Aminobutyric Acid (GABA)”, Krantis, et al.,Digestive Diseases and Sciences, vol. 34, No. 8m pp. 1211-1216, Aug. 1989.
“Augmentation of γ-Globin Gene Promotor Activity by Carboxylic Acids and Components of the Human β-Glovin Locus Control Region”, S. Safaya et al.,Blood, vol. 84, No. 11, Dec. 1, 1994, pp. 3929-3925.
“Biological Effects of Short-Chain Fatty Acids in Nonruminant Mammals”, Maurice Bugaut, et al.,Annu. Rev. Nutr., vol. 13. pp. 217-241, 1993.
“Butyric Acid: A Small Fatty Acid With Diverse Biological Functions”, Kedar N. Prasad,Life Sciences, vol. 27, pp. 1351-1358.
“Butyric acid-induced differentiation of HL-60 cells increases the expression of a single lysophospholipase”, Diane Garsetti et al,Biochem. J. vol. 288, 1992, pp. 831-837.
“Butyrate Acid in the Treatment of Cancer”, James Watson, et al.,The Lancet, pp. 746-748, Apr. 8, 1933.
“Butyric acid suppression of the in vitro neoplastic state of Syrian hamster cells”, J. Leavitt et al,Naturevol. 271, Jan. 19, 1978, pp. 262-265.
“Butyrate Induces Selective Transcriptional Activation of a Hympmethylated Embryonic Globe Gene in Adult Erythroid Cells”, Linda J. Burns, et al.,Blood, vol. 72, No. 5, pp. 1536-1542, 1988.
“Cell Differentiation and Bypassing of Genetic Defects in the Suppression of Malignancy”, L. Sachs,Cancer Research, vol. 47, Apr. 15, 1987, pp. 1981-1986.
“Characterization of deletions which affect the expression of fetal globin genes in man”, Edward F. Fritsch et al., Division of Biology, California Institute of Technology, Pasadena, California, Apr. 1979.
“Combinations of retinoic acid with either sodium butyrate, dimethyl, sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeoid leukemia cell line HL60”, T.R. Breitman, et al.,Cancer Research, vol. 50, pp. 6268-6273, Oct. 1, 1990.
“Comm
Faller Douglas V.
Perrine Susan P.
Betton Timothy E
Nixon & Peabody LLP
Padmanabhan Sreeni
The Trustees of Boston University
LandOfFree
Compositions for the treatment of blood disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the treatment of blood disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the treatment of blood disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705410